TY - JOUR
T1 - Detection of 300-kilodalton membrane protein in adriamycin-resistant human tumor cells by a monoclonal antibody MRK18
AU - Sugimoto, Yoshikazu
AU - Okochi, Etsuko
AU - Hamada, Hirofumi
AU - Oh-hara, Tomoko
AU - Tsuruo, Takashi
N1 - Funding Information:
Gottesman for kindly providing us drug-resistant and -sensitive tumor lines. We thank T. Toyama for preparing the typescript. This work was supported partly by grants from the Ministry of Education, Science and Culture, Japan, from the Ministry of Health and Welfare, Japan, and from the Foundation for Promotion of Cancer Research, Japan.
PY - 1990/6/15
Y1 - 1990/6/15
N2 - To characterize the membrane changes related to adriamycin (ADM) resistance in tumor cells, we have developed monoclonal antibodies against an ADM-resistant subline of human myelogenous leukemia K562 ( K562 ADM), and reported the overexpression of P-glycoprotein and 85-kDa protein as determined by the antibodies. In the present study, we have established a monoclonal antibody, MRK18, with higher reactivity to K562 ADM than to K562. MRK18 also showed higher reactivity to other human ADM-resistant lines, 2780AD and Hattori/ADM, than the corresponding parental lines. MRK18 also reacted to human breast cancer MCF-7 and human T-lymphoma CCRF-CEM which have never been exposed to anticancer agents in culture. MRK18 recognized a 300-kDa membrane protein of K562 ADM and MCF-7 and inhibited the growth of these cell lines in culture. These results indicate an induction of the 300-kDa protein during the development of ADM resistance.
AB - To characterize the membrane changes related to adriamycin (ADM) resistance in tumor cells, we have developed monoclonal antibodies against an ADM-resistant subline of human myelogenous leukemia K562 ( K562 ADM), and reported the overexpression of P-glycoprotein and 85-kDa protein as determined by the antibodies. In the present study, we have established a monoclonal antibody, MRK18, with higher reactivity to K562 ADM than to K562. MRK18 also showed higher reactivity to other human ADM-resistant lines, 2780AD and Hattori/ADM, than the corresponding parental lines. MRK18 also reacted to human breast cancer MCF-7 and human T-lymphoma CCRF-CEM which have never been exposed to anticancer agents in culture. MRK18 recognized a 300-kDa membrane protein of K562 ADM and MCF-7 and inhibited the growth of these cell lines in culture. These results indicate an induction of the 300-kDa protein during the development of ADM resistance.
UR - http://www.scopus.com/inward/record.url?scp=0025374517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025374517&partnerID=8YFLogxK
U2 - 10.1016/0006-291X(90)90385-Z
DO - 10.1016/0006-291X(90)90385-Z
M3 - Article
C2 - 1972622
AN - SCOPUS:0025374517
SN - 0006-291X
VL - 169
SP - 686
EP - 691
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 2
ER -
